This document discusses liquid biopsies, which are non-invasive blood tests that detect circulating tumor cells and fragments of tumor DNA shed into the blood. Liquid biopsies provide information about cancers without invasive biopsy by analyzing biomarkers like circulating tumor cells, circulating tumor DNA, exosomes, and tumor-educated platelets. The document outlines the potential uses of liquid biopsy in cancer detection, diagnosis, monitoring treatment efficacy, and detecting recurrence. While tissue biopsy remains the gold standard, liquid biopsy is becoming more useful as technology advances and may provide information when a tissue biopsy is not possible or reveals limited information.
Liquid Biopsy Overview, Challenges and New Solutions: Liquid Biopsy Series Pa...QIAGEN
A liquid biopsy is often described as a sensitive and specific blood test to detect circulating tumor cells (CTCs). CTCs, shed by both the primary and metastasized tumors, carry specific information about their origins and markers that will enable us to discover new diagnosis, prognosis and therapeutic targets. This slidedeck gives an overview of the recent progress in exploring the predictive potential of circulating biomarkers, including circulating tumor cells, circulating tumor DNA, microRNAs, long non-coding RNAs (lncRNAs) and exosomes. Addressing both biological and technical aspects, we detail the isolation and characterization of circulating biomarkers. Challenges and solutions are also featured.
Molecular characterization of a patient’s tumor to guide treatment decisions is increasingly being
applied in clinical care and can have a significant impact on disease outcome. These molecular analyses,
including mutation characterization, are typically performed on tissue acquired through a biopsy at diagnosis.
However, tumors are highly heterogeneous and sampling in its entirety is challenging. Furthermore, tumors
evolve over time and can alter their molecular genotype, making clinical decisions based on historical biopsy
data suboptimal. Personalized medicine for cancer patients aims to tailor the best treatment options for the
individual at diagnosis and during treatment. To fully enable personalized medicine it is desirable to have an
easily accessible, minimally invasive way to determine and follow the molecular makeup of a patient’s tumor
longitudinally. One such approach is through a liquid biopsy, where the genetic makeup of the tumor can be
assessed through a bio fluid sample. Liquid biopsies have the potential to help clinicians screen for disease,
stratify patients to the best treatment and monitor treatment response and resistance mechanisms in the tumor. A liquid biopsy can be used for molecular characterization of the tumor and its non-invasive nature
allows repeat sampling to monitor genetic changes over time without the need for a tissue biopsy. This review will summarize three approaches in the liquid biopsy field: circulating tumor cells (CTCs), cell free DNA (cfDNA) and exosomes. We also outline some of the analytical challenges encountered using liquid biopsy techniques to detect rare mutations in a background of wild-type sequences.
Innovations in Liquid Biopsies for Precision Cancer DiagnosisClinosolIndia
Precision medicine, with its focus on tailoring medical interventions to individual characteristics, benefits significantly from the integration of machine learning (ML) algorithms for predictive analytics. These algorithms analyze complex datasets, identify patterns, and generate predictions that inform personalized treatment strategies. This article explores the diverse applications of ML in precision medicine, highlighting the key algorithms driving predictive analytics in this transformative field.
Liquid Biopsy Overview, Challenges and New Solutions: Liquid Biopsy Series Pa...QIAGEN
A liquid biopsy is often described as a sensitive and specific blood test to detect circulating tumor cells (CTCs). CTCs, shed by both the primary and metastasized tumors, carry specific information about their origins and markers that will enable us to discover new diagnosis, prognosis and therapeutic targets. This slidedeck gives an overview of the recent progress in exploring the predictive potential of circulating biomarkers, including circulating tumor cells, circulating tumor DNA, microRNAs, long non-coding RNAs (lncRNAs) and exosomes. Addressing both biological and technical aspects, we detail the isolation and characterization of circulating biomarkers. Challenges and solutions are also featured.
Molecular characterization of a patient’s tumor to guide treatment decisions is increasingly being
applied in clinical care and can have a significant impact on disease outcome. These molecular analyses,
including mutation characterization, are typically performed on tissue acquired through a biopsy at diagnosis.
However, tumors are highly heterogeneous and sampling in its entirety is challenging. Furthermore, tumors
evolve over time and can alter their molecular genotype, making clinical decisions based on historical biopsy
data suboptimal. Personalized medicine for cancer patients aims to tailor the best treatment options for the
individual at diagnosis and during treatment. To fully enable personalized medicine it is desirable to have an
easily accessible, minimally invasive way to determine and follow the molecular makeup of a patient’s tumor
longitudinally. One such approach is through a liquid biopsy, where the genetic makeup of the tumor can be
assessed through a bio fluid sample. Liquid biopsies have the potential to help clinicians screen for disease,
stratify patients to the best treatment and monitor treatment response and resistance mechanisms in the tumor. A liquid biopsy can be used for molecular characterization of the tumor and its non-invasive nature
allows repeat sampling to monitor genetic changes over time without the need for a tissue biopsy. This review will summarize three approaches in the liquid biopsy field: circulating tumor cells (CTCs), cell free DNA (cfDNA) and exosomes. We also outline some of the analytical challenges encountered using liquid biopsy techniques to detect rare mutations in a background of wild-type sequences.
Innovations in Liquid Biopsies for Precision Cancer DiagnosisClinosolIndia
Precision medicine, with its focus on tailoring medical interventions to individual characteristics, benefits significantly from the integration of machine learning (ML) algorithms for predictive analytics. These algorithms analyze complex datasets, identify patterns, and generate predictions that inform personalized treatment strategies. This article explores the diverse applications of ML in precision medicine, highlighting the key algorithms driving predictive analytics in this transformative field.
Circulating Tumor Cells and Cell-Free Nucleic Acids as Predictor Factors for ...daranisaha
Pancreatic cancer remains as one of the most aggressive and deadliest of cancers largely due to formidable challenges in diagnosis and therapy. Consensus standard treatment for patients with nonmetastatic Pancreatic Cancer (PC) incorporates possible neoadjuvant chemotherapy with timely surgical resection and adjuvant chemotherapy. However, despite all the sophistication of modern radiological and endoscopic techniques, the decision regarding operability is often only made intra-operatively, therefore subjecting a patient to unnecessary surgical intervention, and postponing the possibility of starting early chemotherapy.
Circulating Tumor Cells and Cell-Free Nucleic Acids as Predictor Factors for ...AnonIshanvi
Pancreatic cancer remains as one of the most aggressive and deadliest of cancers largely due to formidable challenges in diagnosis and therapy. Consensus standard treatment for patients with nonmetastatic Pancreatic Cancer (PC) incorporates possible neoadjuvant chemotherapy with timely surgical resection and adjuvant chemotherapy. However, despite all the sophistication of modern radiological and endoscopic techniques, the decision regarding operability is often only made intra-operatively, therefore subjecting a patient to unnecessary surgical intervention, and postponing the possibility of starting early chemotherapy.
Circulating Tumor Cells and Cell-Free Nucleic Acids as Predictor Factors for ...JohnJulie1
Pancreatic cancer remains as one of the most aggressive and deadliest of cancers largely due to formidable challenges in diagnosis and therapy. Consensus standard treatment for patients with nonmetastatic Pancreatic Cancer (PC) incorporates possible neoadjuvant chemotherapy with timely surgical resection and adjuvant chemotherapy. However, despite all the sophistication of modern radiological and endoscopic techniques, the decision regarding operability is often only made intra-operatively, therefore subjecting a patient to unnecessary surgical intervention, and postponing the possibility of starting early chemotherapy.
Circulating Tumor Cells and Cell-Free Nucleic Acids as Predictor Factors for ...semualkaira
Pancreatic cancer remains as one of the most
aggressive and deadliest of cancers largely due to formidable challenges in diagnosis and therapy. Consensus standard treatment for
patients with nonmetastatic Pancreatic Cancer (PC) incorporates
possible neoadjuvant chemotherapy with timely surgical resection
and adjuvant chemotherapy. However, despite all the sophistication of modern radiological and endoscopic techniques, the decision regarding operability is often only made intra-operatively,
therefore subjecting a patient to unnecessary surgical intervention,
and postponing the possibility of starting early chemotherapy.
Circulating Tumor Cells and Cell-Free Nucleic Acids as Predictor Factors for ...EditorSara
Pancreatic cancer remains as one of the most aggressive and deadliest of cancers largely due to formidable challenges in diagnosis and therapy. Consensus standard treatment for patients with nonmetastatic Pancreatic Cancer (PC) incorporates possible neoadjuvant chemotherapy with timely surgical resection and adjuvant chemotherapy. However, despite all the sophistication of modern radiological and endoscopic techniques, the decision regarding operability is often only made intra-operatively, therefore subjecting a patient to unnecessary surgical intervention, and postponing the possibility of starting early chemotherapy.
Circulating Tumor Cells and Cell-Free Nucleic Acids as Predictor Factors for ...EditorSara
Pancreatic cancer remains as one of the most aggressive and deadliest of cancers largely due to formidable challenges in diagnosis and therapy. Consensus standard treatment for patients with nonmetastatic Pancreatic Cancer (PC) incorporates possible neoadjuvant chemotherapy with timely surgical resection and adjuvant chemotherapy. However, despite all the sophistication of modern radiological and endoscopic techniques, the decision regarding operability is often only made intra-operatively, therefore subjecting a patient to unnecessary surgical intervention, and postponing the possibility of starting early chemotherapy.
Circulating Tumor Cells and Cell-Free Nucleic Acids as Predictor Factors for ...semualkaira
Pancreatic cancer remains as one of the most
aggressive and deadliest of cancers largely due to formidable challenges in diagnosis and therapy. Consensus standard treatment for
patients with nonmetastatic Pancreatic Cancer (PC) incorporates
possible neoadjuvant chemotherapy with timely surgical resection
and adjuvant chemotherapy
Circulating Tumor Cells and Cell-Free Nucleic Acids as Predictor Factors for ...semualkaira
Pancreatic cancer remains as one of the most aggressive and deadliest of cancers largely due to formidable challenges in diagnosis and therapy. Consensus standard treatment for patients with nonmetastatic Pancreatic Cancer (PC) incorporates possible neoadjuvant chemotherapy with timely surgical resection and adjuvant chemotherapy. However, despite all the sophistication of modern radiological and endoscopic techniques, the decision regarding operability is often only made intra-operatively, therefore subjecting a patient to unnecessary surgical intervention, and postponing the possibility of starting early chemotherapy.
Circulating Tumor Cells and Cell-Free Nucleic Acids as Predictor Factors for ...NainaAnon
Pancreatic cancer remains as one of the most aggressive and deadliest of cancers largely due to formidable challenges in diagnosis and therapy. Consensus standard treatment for patients with nonmetastatic Pancreatic Cancer (PC) incorporates possible neoadjuvant chemotherapy with timely surgical resection and adjuvant chemotherapy. However, despite all the sophistication of modern radiological and endoscopic techniques, the decision regarding operability is often only made intra-operatively, therefore subjecting a patient to unnecessary surgical intervention, and postponing the possibility of starting early chemotherapy.
Circulating Tumor Cells and Cell-Free Nucleic Acids as Predictor Factors for ...semualkaira
Pancreatic cancer remains as one of the most
aggressive and deadliest of cancers largely due to formidable challenges in diagnosis and therapy. Consensus standard treatment for
patients with nonmetastatic Pancreatic Cancer (PC) incorporates
possible neoadjuvant chemotherapy with timely surgical resection
and adjuvant chemotherapy
As the techniques that have enabled us to analyses and assess a biopsy become ever more sophisticated, we have realised the limitations of looking at the single snap-shot of the tumour. This single-biopsy bias was highlighted in which it was mainly demonstrated that a portion taken from different parts of a primary tumour and its metastases showed and proved extensive intertumoural and intratumoural evolution. This tumoural heterogeneity mainly highlights the difficulty of dictating a therapeutic course of action based on the single biopsy, as it is likely to underestimate the ramification of the genomic landscape of the tumour (Chomczynski et al., 2016).Having established that there is mainly considerable tumour heterogeneity, taking multiple biopsies from the patients‘ primary tumour and the metastases would seem to be the most obvious next step. There are so much difficulties in obtaining the tissue biopsy— including the discomfort suffered by the patient, the inherent clinical risks to the patient
Circulating Tumor Cells and Cell-Free Nucleic Acids as Predictor Factors for ...daranisaha
Pancreatic cancer remains as one of the most aggressive and deadliest of cancers largely due to formidable challenges in diagnosis and therapy. Consensus standard treatment for patients with nonmetastatic Pancreatic Cancer (PC) incorporates possible neoadjuvant chemotherapy with timely surgical resection and adjuvant chemotherapy. However, despite all the sophistication of modern radiological and endoscopic techniques, the decision regarding operability is often only made intra-operatively, therefore subjecting a patient to unnecessary surgical intervention, and postponing the possibility of starting early chemotherapy.
Circulating Tumor Cells and Cell-Free Nucleic Acids as Predictor Factors for ...AnonIshanvi
Pancreatic cancer remains as one of the most aggressive and deadliest of cancers largely due to formidable challenges in diagnosis and therapy. Consensus standard treatment for patients with nonmetastatic Pancreatic Cancer (PC) incorporates possible neoadjuvant chemotherapy with timely surgical resection and adjuvant chemotherapy. However, despite all the sophistication of modern radiological and endoscopic techniques, the decision regarding operability is often only made intra-operatively, therefore subjecting a patient to unnecessary surgical intervention, and postponing the possibility of starting early chemotherapy.
Circulating Tumor Cells and Cell-Free Nucleic Acids as Predictor Factors for ...JohnJulie1
Pancreatic cancer remains as one of the most aggressive and deadliest of cancers largely due to formidable challenges in diagnosis and therapy. Consensus standard treatment for patients with nonmetastatic Pancreatic Cancer (PC) incorporates possible neoadjuvant chemotherapy with timely surgical resection and adjuvant chemotherapy. However, despite all the sophistication of modern radiological and endoscopic techniques, the decision regarding operability is often only made intra-operatively, therefore subjecting a patient to unnecessary surgical intervention, and postponing the possibility of starting early chemotherapy.
Circulating Tumor Cells and Cell-Free Nucleic Acids as Predictor Factors for ...semualkaira
Pancreatic cancer remains as one of the most
aggressive and deadliest of cancers largely due to formidable challenges in diagnosis and therapy. Consensus standard treatment for
patients with nonmetastatic Pancreatic Cancer (PC) incorporates
possible neoadjuvant chemotherapy with timely surgical resection
and adjuvant chemotherapy. However, despite all the sophistication of modern radiological and endoscopic techniques, the decision regarding operability is often only made intra-operatively,
therefore subjecting a patient to unnecessary surgical intervention,
and postponing the possibility of starting early chemotherapy.
Circulating Tumor Cells and Cell-Free Nucleic Acids as Predictor Factors for ...EditorSara
Pancreatic cancer remains as one of the most aggressive and deadliest of cancers largely due to formidable challenges in diagnosis and therapy. Consensus standard treatment for patients with nonmetastatic Pancreatic Cancer (PC) incorporates possible neoadjuvant chemotherapy with timely surgical resection and adjuvant chemotherapy. However, despite all the sophistication of modern radiological and endoscopic techniques, the decision regarding operability is often only made intra-operatively, therefore subjecting a patient to unnecessary surgical intervention, and postponing the possibility of starting early chemotherapy.
Circulating Tumor Cells and Cell-Free Nucleic Acids as Predictor Factors for ...EditorSara
Pancreatic cancer remains as one of the most aggressive and deadliest of cancers largely due to formidable challenges in diagnosis and therapy. Consensus standard treatment for patients with nonmetastatic Pancreatic Cancer (PC) incorporates possible neoadjuvant chemotherapy with timely surgical resection and adjuvant chemotherapy. However, despite all the sophistication of modern radiological and endoscopic techniques, the decision regarding operability is often only made intra-operatively, therefore subjecting a patient to unnecessary surgical intervention, and postponing the possibility of starting early chemotherapy.
Circulating Tumor Cells and Cell-Free Nucleic Acids as Predictor Factors for ...semualkaira
Pancreatic cancer remains as one of the most
aggressive and deadliest of cancers largely due to formidable challenges in diagnosis and therapy. Consensus standard treatment for
patients with nonmetastatic Pancreatic Cancer (PC) incorporates
possible neoadjuvant chemotherapy with timely surgical resection
and adjuvant chemotherapy
Circulating Tumor Cells and Cell-Free Nucleic Acids as Predictor Factors for ...semualkaira
Pancreatic cancer remains as one of the most aggressive and deadliest of cancers largely due to formidable challenges in diagnosis and therapy. Consensus standard treatment for patients with nonmetastatic Pancreatic Cancer (PC) incorporates possible neoadjuvant chemotherapy with timely surgical resection and adjuvant chemotherapy. However, despite all the sophistication of modern radiological and endoscopic techniques, the decision regarding operability is often only made intra-operatively, therefore subjecting a patient to unnecessary surgical intervention, and postponing the possibility of starting early chemotherapy.
Circulating Tumor Cells and Cell-Free Nucleic Acids as Predictor Factors for ...NainaAnon
Pancreatic cancer remains as one of the most aggressive and deadliest of cancers largely due to formidable challenges in diagnosis and therapy. Consensus standard treatment for patients with nonmetastatic Pancreatic Cancer (PC) incorporates possible neoadjuvant chemotherapy with timely surgical resection and adjuvant chemotherapy. However, despite all the sophistication of modern radiological and endoscopic techniques, the decision regarding operability is often only made intra-operatively, therefore subjecting a patient to unnecessary surgical intervention, and postponing the possibility of starting early chemotherapy.
Circulating Tumor Cells and Cell-Free Nucleic Acids as Predictor Factors for ...semualkaira
Pancreatic cancer remains as one of the most
aggressive and deadliest of cancers largely due to formidable challenges in diagnosis and therapy. Consensus standard treatment for
patients with nonmetastatic Pancreatic Cancer (PC) incorporates
possible neoadjuvant chemotherapy with timely surgical resection
and adjuvant chemotherapy
As the techniques that have enabled us to analyses and assess a biopsy become ever more sophisticated, we have realised the limitations of looking at the single snap-shot of the tumour. This single-biopsy bias was highlighted in which it was mainly demonstrated that a portion taken from different parts of a primary tumour and its metastases showed and proved extensive intertumoural and intratumoural evolution. This tumoural heterogeneity mainly highlights the difficulty of dictating a therapeutic course of action based on the single biopsy, as it is likely to underestimate the ramification of the genomic landscape of the tumour (Chomczynski et al., 2016).Having established that there is mainly considerable tumour heterogeneity, taking multiple biopsies from the patients‘ primary tumour and the metastases would seem to be the most obvious next step. There are so much difficulties in obtaining the tissue biopsy— including the discomfort suffered by the patient, the inherent clinical risks to the patient
Defecation
Normal defecation begins with movement in the left colon, moving stool toward the anus. When stool reaches the rectum, the distention causes relaxation of the internal sphincter and an awareness of the need to defecate. At the time of defecation, the external sphincter relaxes, and abdominal muscles contract, increasing intrarectal pressure and forcing the stool out
The Valsalva maneuver exerts pressure to expel faeces through a voluntary contraction of the abdominal muscles while maintaining forced expiration against a closed airway. Patients with cardiovascular disease, glaucoma, increased intracranial pressure, or a new surgical wound are at greater risk for cardiac dysrhythmias and elevated blood pressure with the Valsalva maneuver and need to avoid straining to pass the stool.
Normal defecation is painless, resulting in passage of soft, formed stool
CONSTIPATION
Constipation is a symptom, not a disease. Improper diet, reduced fluid intake, lack of exercise, and certain medications can cause constipation. For example, patients receiving opiates for pain after surgery often require a stool softener or laxative to prevent constipation. The signs of constipation include infrequent bowel movements (less than every 3 days), difficulty passing stools, excessive straining, inability to defecate at will, and hard feaces
IMPACTION
Fecal impaction results from unrelieved constipation. It is a collection of hardened feces wedged in the rectum that a person cannot expel. In cases of severe impaction the mass extends up into the sigmoid colon.
DIARRHEA
Diarrhea is an increase in the number of stools and the passage of liquid, unformed feces. It is associated with disorders affecting digestion, absorption, and secretion in the GI tract. Intestinal contents pass through the small and large intestine too quickly to allow for the usual absorption of fluid and nutrients. Irritation within the colon results in increased mucus secretion. As a result, feces become watery, and the patient is unable to control the urge to defecate. Normally an anal bag is safe and effective in long-term treatment of patients with fecal incontinence at home, in hospice, or in the hospital. Fecal incontinence is expensive and a potentially dangerous condition in terms of contamination and risk of skin ulceration
HEMORRHOIDS
Hemorrhoids are dilated, engorged veins in the lining of the rectum. They are either external or internal.
FLATULENCE
As gas accumulates in the lumen of the intestines, the bowel wall stretches and distends (flatulence). It is a common cause of abdominal fullness, pain, and cramping. Normally intestinal gas escapes through the mouth (belching) or the anus (passing of flatus)
FECAL INCONTINENCE
Fecal incontinence is the inability to control passage of feces and gas from the anus. Incontinence harms a patient’s body image
PREPARATION AND GIVING OF LAXATIVESACCORDING TO POTTER AND PERRY,
An enema is the instillation of a solution into the rectum and sig
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
4. INTRODUCTION
• The diagnosis of cancer has undergone a
paradigm shift.
• No longer is cancer diagnosed only based
on morphological parameters.
• More and more the diagnostic algorithm is
supported by immunohistochemical and
molecular alterations at the DNA, mRNAs,
miRNAs and proteomic level.
5. INTRODUCTION
• Multiple platforms and technological
advances enable faster and cheaper analysis
of all these as well as the whole genome.
• Recent scientific advances in understanding
circulating tumor cells, cell-free DNA/RNA,
and exosomes in blood have laid a solid
foundation for the development of routine
molecular ‘liquid biopsies’.
6. INTRODUCTION
• This approach provides non-invasive access
to genetic information – somatic mutations,
epigenetic changes, and differential
expression – about the physiological
conditions of body and diseases.
• Liquid biopsy has the potential to provide
information about cancers without invasive
biopsy, using circulating biomarkers.
7. INTRODUCTION
• It opens a valuable avenue for cancer
screening and monitoring.
• With the rapid development of highly sensitive
and accurate technologies such as next-
generation sequencing, molecular ‘liquid
biopsies’ will quickly become a central piece
in the future.
8. INTRODUCTION
• These include proteins, RNAs and DNAs.
They can be used in,
• Detection
• Diagnosis
• Monitoring and
• Detection of recurrence of cancer.
• While protein-based tumour markers have
been used in routine pathology for many
years, the ability to detect mutations in
circulating DNA is relatively new.
9. DEFINITION
• Liquid biopsies are non-invasive
blood tests that detect circulating
tumour cells (CTCs) and fragments
of tumor DNA that are shed into
the blood from the primary tumour
and from metastatic sites.
13. CIRCULATING TUMOR CELLS
• During late 19th century, T.R. Ashworth
first described the presence of epithelial
cells in the blood of a woman with
metastatic breast cancer that were similar
in appearance to her primary tumor cells.
• Indeed, many patients with a variety of
solid tumors, including breast cancer, have
detectable cancer cells circulating in the
bloodstream, so-called circulating tumor
cells (CTCs).
14. CIRCULATING TUMOR CELLS
• CTCs represent a rare cell population in
the blood, typically less than 10 cells/mL
compared with 1 million WBCs/mL
• However, the detection of CTCs within a
routine blood specimen provides an
opportunity to monitor cancer non-
invasively, in essence a liquid biopsy.
27. • Besides tumor cells and their products,
normal cells present in the tumor
microenvironment are also released
into the blood stream.
• These cells can harbor important
information about the tumor.
28. • Among which platelets have been
studied extensively and gave promising
results.
• The biology behind this new diagnostic
role of Tumor Educated Platelets
(TEPs) is the well-known interaction
between blood platelets and tumor
cells
29. • This interaction affects not only the
expression of relevant genes in tumor
cells, but also alters the RNA profile
of blood platelets.
• mRNA sequencing of TEPs can be
distinguished from the platelets of
healthy individuals.
30.
31. INDICATION OF LIQUID BIOSPY
• To monitor residual disease in patients
with known mutations in the primary
tumor.
• To monitor treatment efficacy in patients
• To monitor disease progression and
tumor evolution (i.e. development of
tumor resistance).
32. • Help the physician explore other
options of treatment when the patient
is resistant to current therapies.
• Provide an alternative method for
biopsy when tissue is difficult to
obtain or not available, or when the
primary site of metastatic disease is
unknown.
33. • It also provide an alternative method for
biopsy when the quantity of tissue
obtained in a biopsy sample is limited and
traditional molecular genotyping is
requested.
• Provide prognostic information.
34. CANCER AND SOMATIC
MUTATIONS
• The majority of cancers arise after a series
of somatic gene mutations that
accumulate during an individual’s lifetime
• Identifying and understanding the somatic
alterations in an individual’s tumor can be
crucial in cancer diagnosis and in planning
personalized cancer treatment, monitoring
response to therapy, and identifying
cancer recurrence
35. CANCER AND SOMATIC
MUTATIONS
• Moreover, as a tumor progresses, some
times it continues to acquire additional
alterations that can affect the response to
therapeutic agents such as chemotherapy
or targeted therapies.
• Distant metastases can harbor unique
genomic characteristics not detectable in
the corresponding primary tumor of the
same patient
36. CANCER AND SOMATIC
MUTATIONS
• Moreover, metastases located at different
sites show a considerable intra-patient
heterogeneity.
• Thus, the mere analysis of the resected
primary tumor alone (current standard
practice in oncology) or, if possible, even re-
evaluation of tumor characteristics based on
the biopsy of the most accessible metastasis
may not reveal sufficient information for
treatment decisions
37.
38. Novel diagnostic biomarkers used in the
clinic for various types of cancers and their
targeted drug therapy.
39.
40.
41.
42. Is this the end of tissue biopsies?
“Tissue biopsy will remain the gold standard
for the next couple of years. As scientific
knowledge advances, researchers are
learning more about the potential of liquid
biopsies to detect mutations.
43. • At the moment, liquid biopsies are
recommended when a tissue biopsy is
difficult, such as in the case of lung
cancer, or when the original site of the
disease is unknown.
44. Liquid biopsies have a powerful role in
helping patients get to the right treatment.
45. CONCLUSION
• Molecular analysis of cancer is required to
optimise patient treatment
• New methods such as next generation
sequencing show immense promise for the
future
• Liquid biopsy is coming of age and will
change practice – it will enable oncologists
to use drugs intelligently to combat
changes in individual cancers as they
happen
46.
47.
48.
49.
50.
51.
52. references
• Tumor-Educated Platelets as Liquid
Biopsy in Cancer Patients (PDF Download
Available). Available from:
https://www.researchgate.net/publication/2
84112407_Tumor-
Educated_Platelets_as_Liquid_Biopsy_in_
Cancer_Patients [accessed Jul 18, 2017].